FDA Safety Act Proposes Fines For Failure To Comply With Drug Safety Office
This article was originally published in The Pink Sheet Daily
Executive Summary
Center for Postmarket Drug Evaluation & Research would be able to levy fines starting at $250,000 for failure to complete postmarketing studies on time and for failure to comply with "corrective actions" under the legislation. FDASA would give the independent drug safety office authority over labeling changes and promotional materials.
You may also be interested in...
House Ag Approps Bill Passes Committee With Postmarketing Mandate
FDA could require “one or more studies” of approved drugs to evaluate significant safety concerns, the language says.
House Ag Approps Bill Passes Committee With Postmarketing Mandate
FDA could require “one or more studies” of approved drugs to evaluate significant safety concerns, the language says.
GAO Drug Safety Report Could Reignite Interest In FDA Reform
Sen. Grassley argues that the report, which calls for improvements to FDA’s postmarket drug safety practices, supports reform measures proposed in the FDA Safety Act.